- Home
- SNES vs IMNN Comparison
SNES vs IMNN Comparison
Compare SNES & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNES | IMNN |
|---|---|---|
| Founded | 2004 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 12.5M |
| IPO Year | 2016 | 1985 |
Fundamental Metrics
Financial Performance| Metric | SNES | IMNN |
|---|---|---|
| Price | $1.87 | $3.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 47.6K | 41.6K |
| Earning Date | 03-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | $41.52 | N/A |
| Revenue Next Year | $77.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.37 | N/A |
| 52 Week Low | $1.30 | $2.99 |
| 52 Week High | $6.24 | $41.22 |
Technical Indicators
Market Signals| Indicator | SNES | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 32.98 |
| Support Level | $1.75 | $3.28 |
| Resistance Level | $2.19 | $3.89 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 17.53 | 2.38 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).